A Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
Primary immune thrombocytopenia (ITP) is a condition where the immune system mistakenly destroys platelets, which are cells that help stop bleeding. This leads to a low number of platelets, making it ...
Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Non-small Cell Lung Cancer (NSCLC), Ovarian Cancer, or Breast Cancer
To evaluate the efficacy of romiplostim for the treatment of CIT in patients receiving chemotherapy for the treatment of NSCLC, ovarian cancer, or breast cancer measured by the ability to administer o...
A Study of Selinexor Monotherapy in Subjects with JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia
The main purpose of this study with corresponding optional expansion is to evaluate the efficacy of selinexor in JAKi-naïve participants with myelofibrosis (MF) and moderate thrombocytopenia based on ...
A Study to Assess the Efficacy and Safety of Efgartigimod IV in Adult Participants With Primary Immune Thrombocytopenia
The main purpose of this study is to look at the effect (efficacy) and safety of efgartigimod IV in participants with primary immune thrombocytopenia (ITP). After an up to 2 weeks screening period, el...
A Phase 2 Study of VLX-1005 Versus Placebo in Suspected Heparin Induced Thrombocytopenia
The purpose of this study is to evaluate the efficacy and safety of VLX-1005, a 12-lipoxygenase (12-LOX) enzyme inhibitor in treating heparin induced thrombocytopenia (HIT). Participants with suspecte...
A Study of Pirtobrutinib in Participants With Immune Thrombocytopenia
The purpose of the phase 1 part of this study is to evaluate how well pirtobrutinib is tolerated and what side effects may occur. The phase 2 part of the study will further investigate efficacy and sa...
A Study Investigating Intravenous Human Normal Immunoglobulin 10% in Adults With Chronic Immune Thrombocytopenia (ITP)
The purpose of this study is to evaluate the efficacy and safety of KIg 10 (Intravenous Immunoglobulin 10%) in adult patients with chronic primary ITP...
Top Cities for Thrombocytopenia Clinical Trials
Thrombocytopenia clinical trials are recruiting across 52 cities. Here are the cities with the most active studies:
About Thrombocytopenia
Thrombocytopenia is a condition characterized by abnormally low levels of platelets, which help blood clot. Immune thrombocytopenia (ITP) is a common autoimmune cause. Treatment may include corticosteroids, immunoglobulins, thrombopoietin receptor agonists, and splenectomy.
Clinical trials are advancing new treatments for thrombocytopenia. Currently, 7 studies are recruiting a combined 672 participants across the United States. Research is being conducted by 7 organizations including Takeda, Amgen, Karyopharm Therapeutics Inc and 4 others.
2026 Thrombocytopenia Research Landscape
As of March 2026, the thrombocytopenia clinical trial landscape includes 7 actively recruiting studies across 52 cities in the United States. These studies are collectively seeking 672 participants, with an average enrollment target of 96 per study.
Research is being led by 7 different organizations, including Takeda, Amgen, Karyopharm Therapeutics Inc, argenx, Veralox Therapeutics, and 2 others.
Geographically, thrombocytopenia trials are most concentrated in Washington D.C., District of Columbia (5 trials); Los Angeles, California (4 trials); Durham, North Carolina (3 trials); Philadelphia, Pennsylvania (3 trials); Iowa City, Iowa (2 trials) and 7 other cities.
Featured Thrombocytopenia Studies
Highlighted recruiting studies for thrombocytopenia, selected by enrollment size and research scope.
A Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
Primary immune thrombocytopenia (ITP) is a condition where the immune system mistakenly destroys platelets, which are cells that help stop bleeding. This leads to a low number of platelets, making it easier to bruise or bleed. The main aim of this study is to learn whether mezagitamab, when given just under the skin (subcutaneously \[SC\]), is effective in keeping the platelet count of adults with...
Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Non-small Cell Lung Cancer (NSCLC), Ovarian Cancer, or Breast Cancer
To evaluate the efficacy of romiplostim for the treatment of CIT in patients receiving chemotherapy for the treatment of NSCLC, ovarian cancer, or breast cancer measured by the ability to administer on-time, full-dose chemotherapy
A Study of Selinexor Monotherapy in Subjects with JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia
The main purpose of this study with corresponding optional expansion is to evaluate the efficacy of selinexor in JAKi-naïve participants with myelofibrosis (MF) and moderate thrombocytopenia based on spleen volume reduction (SVR). Additional efficacy and safety parameters will also be assessed during the study.
Frequently Asked Questions About Thrombocytopenia Clinical Trials
Are there thrombocytopenia clinical trials near me?
Yes, there are 7 thrombocytopenia clinical trials currently recruiting across 52+ cities in the United States, including Washington D.C., District of Columbia; Los Angeles, California; Durham, North Carolina. Browse the studies above to find one at a location convenient for you.
How do I join a thrombocytopenia clinical trial?
To join a thrombocytopenia clinical trial: 1) Browse the available studies on this page, 2) Click on a study that interests you, 3) Check the study locations to find a site near you, 4) Review the eligibility criteria, and 5) Contact the study site or complete the eligibility form. The process is free and you can withdraw at any time.
Are thrombocytopenia clinical trials free?
Yes, participation in thrombocytopenia clinical trials is free. Study-related treatments, medical tests, and doctor visits are provided at no cost to participants. Many studies also offer compensation for your time and travel expenses.
What types of thrombocytopenia treatments are being studied?
Current thrombocytopenia clinical trials are testing a range of approaches. These include new drugs, combination therapies, medical devices, and other interventions sponsored by 7 research organizations.
Is it safe to participate in thrombocytopenia clinical trials?
Clinical trials are carefully regulated by the FDA and institutional review boards (IRBs). All trials must follow strict safety protocols, and participants receive close medical monitoring throughout the study. You can withdraw from a trial at any time without penalty.
Data updated March 1, 2026 from ClinicalTrials.gov
About This Data
Clinical trial information on this page is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health (NIH) and National Library of Medicine (NLM). Study data is refreshed every hour to ensure accuracy.
Medical Disclaimer: The information provided on this page is for informational purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider before making decisions about clinical trial participation or changes to your treatment plan.
Page reviewed by the HelloStudys Research Team · Last updated March 1, 2026 · Data from ClinicalTrials.gov